



# Fast-growing global biopharmaceuticals company & leading provider of affordable medicines



Diversified portfolio of 300+ products across Specialty, Biosimilars, Injectables and Retail Generics



Expansive R&D, manufacturing and commercial capabilities at scale with vertical integration



Robust R&D engine generating 20-30 new retail and injectables product launches consistently per year; focused on high-value, complex products



Accelerated revenue and profit growth outlook with higher cash flow generation and continued deleveraging

## Diversified portfolio delivering sustainable growth...



### Retail Generics

#3 U.S Generics portfolio, shift to complex dosage forms



### Injectables

Expanding portfolio of 40+ institutional products with new differentiated 505(b)(2) injectables for hospitals



### Biosimilars

Drive uptake of 3 commercial biosimilars and expand portfolio with next 5 biosimilars



### AvKARE

Expanding presence across channels & dosage forms



### Specialty

Branded therapies focused on Neurology and Endocrinology - highlighted by CREXTONT® for PD




### International

Market expansion in India, Europe & rest of world

## Adjusted EBITDA growth

\$ in millions



## Financials

**\$3.0 - 3.1B**

+8 to 12% Growth 2025 Net Revenue guidance

**\$740 - 770M**

+8 to 12% Growth 2026 Adj. EBITDA guidance

**3.7X**

Net leverage as of September 30, 2025

NASDAQ

**AMRX**



All data as of October 30, 2025.  
1. Reflects 2025 guidance as of October 30, 2025. Full year 2025 estimates are based on management's expectations for prescription trends, pricing levels, inventory levels, the costs incurred and benefits realized of restructuring activities and the anticipated timing of future product launches and events, among other factors. Adjusted EBITDA is a non-GAAP measure; a discussion of Non-GAAP measures is included in the press release issued on October 30, 2025, available at <https://investors.amneal.com/news/press-releases/>.